<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2014390</article-id><article-id pub-id-type="pmcid-ver">PMC2014390.1</article-id><article-id pub-id-type="pmcaid">2014390</article-id><article-id pub-id-type="pmcaiid">2014390</article-id><article-id pub-id-type="pmid">10930962</article-id><article-id pub-id-type="doi">10.1046/j.1365-2125.2000.00238.x</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacodynamics</subject></subj-group></article-categories><title-group><article-title>Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus&#8208;infected patients with chronic liver disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Khaliq</surname><given-names initials="Y">Yasmin</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gallicano</surname><given-names initials="K">Keith</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="aff" rid="au2">2</xref><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seguin</surname><given-names initials="I">Isabelle</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fyke</surname><given-names initials="K">Kathryn</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Carignan</surname><given-names initials="G">Germain</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bulman</surname><given-names initials="D">Dennis</given-names></name><xref ref-type="aff" rid="au2">2</xref><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Badley</surname><given-names initials="A">Andrew</given-names></name><xref ref-type="aff" rid="au2">2</xref><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cameron</surname><given-names initials="DW">D William</given-names></name><xref ref-type="aff" rid="au2">2</xref><xref ref-type="aff" rid="au3">3</xref></contrib><aff id="au1"><label>1</label><institution>Clinical Investigation Unit, The Ottawa Hospital &#8211; General Campus</institution><addr-line>Ottawa, Ontario, Canada</addr-line></aff><aff id="au2"><label>2</label><institution>Ottawa Hospital Research Institute, The Ottawa Hospital &#8211; General Campus</institution><addr-line>Ottawa, Ontario, Canada</addr-line></aff><aff id="au3"><label>3</label><institution>Department of Medicine, The Ottawa Hospital &#8211; General Campus</institution><addr-line>Ottawa, Ontario, Canada</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><italic>Correspondence:</italic> Keith Gallicano, Ph.D., Axelson Biopharma Research Inc., Suite 309, 2083 Alma Street, Vancouver, British Columbia, Canada V6R 4N6. Tel.: (604) 222&#8211;4184; Fax: (604) 222&#8211;3141; E-mail: <email>kgallicano@axelson.net</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2000</year></pub-date><volume>50</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">151551</issue-id><fpage>108</fpage><lpage>115</lpage><history><date date-type="received"><day>24</day><month>2</month><year>2000</year></date><date date-type="accepted"><day>10</day><month>5</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>02</month><year>2001</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2008</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-10 04:25:28.280"><day>10</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2000 Blackwell Science Ltd</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bcp0050-0108.pdf"/><abstract><sec><title>Aims</title><p>To evaluate the single&#8208;dose and multiple&#8208;dose pharmacokinetics of nelfinavir and its active M8 metabolite in eight HIV&#8208;seropositive patients with liver disease, and to examine the relationship between CYP2C19 activity (genotype and plasma M8/nelfinavir metabolic ratio) and the severity of liver disease in these patients.</p></sec><sec sec-type="methods"><title>Methods</title><p>Nelfinavir was given as a single dose (500 or 750 mg) to patients beginning therapy and twice (500, 750 or 1000 mg) or three times (250 or 750 mg) daily during chronic therapy. Single&#8208;dose pharmacokinetic values were used to predict multiple&#8208;dose regimens. Peak and total plasma exposures between 2&#8211;4 &#181;g ml<sup>&#8722;1</sup> and 45&#8211;75 &#181;g ml<sup>&#8722;1</sup> h, respectively, and predose levels &gt; 0.7 &#181;g ml<sup>&#8722;1</sup> were targeted for multidose nelfinavir. Genotype was determined by analysis for <italic>CYP2C19</italic>*<italic>1</italic>, <italic>CYP2C19</italic>*<italic>2</italic>, and <italic>CYP2C19</italic>*<italic>3</italic>. Individuals were grouped according to their genotype, molar M8/nelfinavir AUC ratio (low: &lt; 0.1, intermediate: 0.1&#8211;0.3, high &gt; 0.3), and Child&#8208;Pugh classification for severity of liver disease.</p></sec><sec><title>Results</title><p>Nelfinavir pharmacokinetics were characterized by wide interindividual variability, low clearance (181&#8211;496 ml min<sup>&#8722;1</sup> 70 kg<sup>&#8722;1</sup>, <italic>n</italic> = 7), and prolonged half-life (5&#8211;20 h, <italic>n</italic> = 7). M8/nelfinavir AUC ratio increased 58% (<italic>n</italic> = 4) and &#945;<sub>1</sub>&#8208;acid glycoprotein levels decreased up to 39% (<italic>n</italic> = 5) from single to multiple dosing. CYP2C19 activity was low (metabolic AUC ratio &lt; 0.1) in four patients with moderate to severe liver disease even though they were genetically extensive CYP2C19 metabolizers (*<italic>1</italic>/*<italic>1</italic> or *<italic>1</italic>/*<italic>2</italic>). Three patients required lower daily doses than the standard regimen of 750 mg every 8 h to achieve target concentrations and maintain virologic suppression at &lt; 50 RNA copies ml<sup>&#8722;1</sup> (up to 20 months).</p></sec><sec><title>Conclusions</title><p>Acquired CYP2C19 deficiency from moderate or severe liver disease resulted in decreased M8 formation. Long&#8208;term HIV suppression is possible using low nelfinavir doses in patients with liver disease.</p></sec></abstract><kwd-group><kwd>CYP2C19</kwd><kwd>liver disease</kwd><kwd>nelfinavir</kwd><kwd>pharmacokinetics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>